G. Eissner, W. Kolch, and P. Scheurich, Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system, Cytokine Growth Factor Rev, vol.15, pp.353-366, 2004.

E. Friedmann, E. Hauben, and K. Maylandt, SPPL2a and SPPL2b promote intramembrane proteolysis of TNFalpha in activated dendritic cells to trigger IL-12 production, Nat Cell Biol, vol.8, pp.843-848, 2006.

S. Kirchner, E. Holler, and S. Haffner, Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes, Cytokine, vol.28, pp.67-74, 2004.

H. Mitoma, T. Horiuchi, and N. Hatta, Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha, Gastroenterology, vol.128, pp.376-392, 2005.

A. Nesbitt, G. Fossati, and M. Bergin, Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents, Inflamm Bowel Dis, vol.13, pp.1323-1332, 2007.

S. S. Bulfone-pau, E. Bulanova, and T. Pohl, Death deflected: IL-15 inhibits TNF-alpha-mediated apoptosis in fibroblasts by TRAF2 recruitment to the IL-15Ralpha chain, FASEB J, vol.13, pp.1575-1585, 1999.

S. Bulfone-paus, D. Ungureanu, and T. Pohl, Interleukin-15 protects from lethal apoptosis in vivo, Nat Med, vol.3, pp.1124-1128, 1997.

E. Mortier, J. Bernard, and A. Plet, Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist, J Immunol, vol.173, pp.1681-1688, 2004.

V. Budagian, E. Bulanova, and Z. Orinska, Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17), J Biol Chem, vol.279, pp.40368-40375, 2004.

E. Mortier, T. Woo, and R. Advincula, IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation, J Exp Med, vol.205, pp.1213-1225, 2008.

G. Bouchaud, L. Garrigue-antar, and V. Solé, The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha, J Mol Biol, vol.382, pp.1-12, 2008.

E. Mortier, A. Quéméner, and P. Vusio, Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of Il-15 action through Il-15R beta/gamma. Herperagonist IL-15 x IL-15R alpha fusion proteins, J Biol Chem, vol.281, pp.1612-1619, 2006.

I. Kirman and O. H. Nielsen, Increased numbers of interleukin-15-expressing cells in active ulcerative colitis, Am J Gastroenterol, vol.91, pp.1789-1794, 1996.

T. Sakai, K. Kusugami, and H. Nishimura, Interleukin 15 activity in the rectal mucosa of inflammatory bowel disease, Gastroenterology, vol.114, pp.1237-1243, 1998.

T. Nishiwaki, K. Ina, and H. Goto, Possible involvement of the interleukin-15 and interleukin-15 receptor system in a heightened state of lamina propria B cell activation and differentiation in patients with inflammatory bowel disease, J Gastroenterol, vol.40, pp.128-136, 2005.

K. Yoshihara, T. Yajima, and C. Kubo, Role of interleukin 15 in colitis induced by dextran sulphate sodium in mice, Gut, vol.55, pp.334-416, 2006.

F. Obermeier, M. Hausmann, and S. Kellermeier, IL-15 protects intestinal epithelial cells, Eur J Immunol, vol.36, pp.2697-2699, 2006.

J. Bernard, C. Harb, and E. Mortier, Identification of an interleukin-15alpha receptor-binding site on human interleukin-15, J Biol Chem, vol.279, pp.24313-24322, 2004.

C. Badoual, G. Bouchaud, A. Nel, and H. , The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer, Cancer Res, vol.68, pp.3907-3914, 2008.

E. H. Duitman, Z. Orinska, and E. Bulanova, How a cytokine is chaperoned through the secretory pathway by complexing with its own receptor: lessons from interleukin-15 (IL-15)/IL-15 receptor alpha, Mol Cell Biol, vol.28, pp.4851-4861, 2008.

V. Dideberg, E. Theatre, and F. Farnir, The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease, Pharmacogenet Genomics, vol.16, pp.727-734, 2006.

Y. Kageyama, M. Takahashi, and . Torikai, Treatment with anti-TNF-alpha antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis, Clin Rheumatol, vol.4, pp.505-509, 2007.

K. Yoshihara, H. Yamada, and A. Hori, IL-15 exacerbates collageninduced arthritis with an enhanced CD4? T cell response to produce IL-17, Eur J Immunol, vol.37, pp.2744-2752, 2007.

H. Ruchatz, B. P. Leung, and X. Wei, Soluble IL-15 receptor alphachain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology, J Immunol, vol.160, pp.5654-5660, 1998.

M. Boirivant, M. Marini, D. Felice, and G. , Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis, Gastroenterology, vol.116, pp.557-565, 1999.

D. Sabatino, A. Ciccocioppo, R. Cinque, and B. , Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease, Gut, vol.53, pp.70-77, 2004.

R. Pereno, A. Gaggero, and M. Scudeletti, IL-15/IL-15R alpha intracellular trafficking in human cells and protection from apoptosis, Ann N Y Acad Sci, vol.876, pp.236-245, 1999.

W. J. Sandborn, P. Rutgeerts, and R. Enns, Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial, Ann Intern Med, vol.146, pp.829-838, 2007.